Clinical Trial Update: Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO [Phase 3]

View source ↗

Summary

Phase 3 study evaluating bone mineral density and bone turnover response to 5 mg daily risedronate in women with postmenopausal osteoporosis; the trial has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• risedronate (risedronate)

Snippet

Sponsor: Warner Chilcott | Conditions: Postmenopausal Osteoporosis | Phase 3 | Status: COMPLETED